Who
Keith Woods
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Scholar Rock Holding; Director, TScan Therapeutics; Director, Neurogene; Director, X4 Pharmaceuticals; Director, Rocket Pharmaceuticals.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $2.4M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 16 Oct 2023
- Last trade
- 24 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 25 Sep 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code G | —48,034 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code G | —48,034 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $507K10,220 at $49.57 | filing |
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $507K10,220 at $49.57 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —47,021 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —47,021 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $715K16,746 at $42.70 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $715K16,746 at $42.70 | filing |
| 30 Jun 2025filed 2 Jul 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 2 May 2025filed 6 May 2025 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,067 at $0.00 | filing |
| 27 Apr 2025filed 29 Apr 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 27 Apr 2025filed 29 Apr 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 14 Jun 2024filed 16 Jun 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.